Banner Image for Directory

Directory



Lam Su Ping, Carolyn

Professor

Email

Bio Research Publications

Professor Carolyn Lam is a Senior Consultant from the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore.  Academically, she serves as a tenured Full Professor at the Duke-National University of Singapore, having also graduated from the Standford Executive Programme in 2015, and obtained a PhD at the University Medical Centre Groningen, the Netherlands in 2016. In the field of MedTech, Prof Lam is co-founder of Us2.ai, an award-wining startup dedicated to the automation of the fight against heart disease by applying artificial intelligence to echocardiography (ultrasound of the heart). 

Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date, respectively. She leads several multinational global and regional clinical trials, and has received numerous prestigious awards and global recognition for her work. Her recent appointments on the 2021 European Society of Cardiology Heart Failure Guidelines Task Force, and as International Honorary Fellow of the Heart Failure Society of America 2021, attest to her contributions in both cardiology and research fields. 

Prof Lam is a proud recipient of the National Medical Research Council (NMRC) Senior Investigator Clinician Scientist Award in 2020, and served as the Founding Programme Lead of A*STaR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT) and Principal Investigator of ASIAN-HF (a multinational study across 11 Asian countries). In 2019, She initiated the Asian Diabetes Outcomes Prevention Trial (ADOPT), an ongoing trial involving 5 countries and aimed at reducing the cardiovascular adverse outcomes of diabetes in Asian patients.

She has published with over 350 articles in major high impact journals including New England Journal of Medicine, Journal of the American Medical Association (JAMA), Lancet, Circulation, and European Heart Journal; and has been recognised as a World Expert by Expertscape’s PubMed-based algorithms (top 0.1% of scholars writing about Heart Failure over the past 10 years; Heart Failure: Worldwide - Expertscape.com). Besides being an Associate Editor for Circulation (top Cardiology Journal) and European Journal of Heart Failure, she is also the lead author of the chapter on HFpEF for Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Edition - the award-winning textbook trusted by generations of cardiologists for the latest, most reliable guidance in the field.

Prof Lam serves as a consultant on several global advisory boards for cardiovascular disease, as a member of the Executive Committees of global heart failure trials, and as an Associate Editor for Circulation and the European Journal of Heart Failure. Finally, she is heard weekly on the global podcast "Circulation On The Run" and seen regularly on television as the Resident Doctor of the health programme "Body and Soul" by MediaCorp Singapore.

 

Education

• Royal College of Physicians of Edinburgh Fellow of the Royal College of Physicians (FRCP), 2018
• University of Groningen, NLD PhD, 2016
• Stanford Graduate School of Business, Stanford Executive Programme, 2015
• Framingham Heart Study, MA, US, Fellowship (Clinical & Genetic Epidemiology), 2010
• Mayo Clinic, Rochester MN, US, Master of Biomedical Science, 2009
• Mayo Clinic, Rochester MN, US, Fellowship (Heart Failure & Advanced Cardiology), 2009
• Ministry of Health, Singapore Specialist Accreditation (Cardiology), 2005
• National University of Singapore, Bachelor of Medicine and Bachelor of Surgery (MBBS), 1998

 

Professional Appointment

  • 2022-23  Content Expert, Clinical Teacher and Clinical Practice Facilitator, Lee Kong Chian School of Medicine
  • 2021-present  Scientific Lead of Imaging – Echo and Theme Principal Investigator HFpEF and Women’s Health and Heart Muscle Disease, National Heart Research Institute Singapore (NHRIS)
  • 2020-present  Principal Lead of Clinical Trials & Trials Network, National Heart Research Institute Singapore (NHRIS)
  • 2020  Degree of Doctor Philosophiae causa, University of Oslo
  • 2019  SingHealth Investigational Medicine Unit Executive Committee, EXCO member
  • 2019  Adjunct Teaching Faculty Member, Lee Kong Chian School of Medicine
  • 2019  Conjoint Professor, University of New South Wales

Committee Memberships

  • 2021-2026  Member, National Clinical Trials Strategy Committee, Ministry of Health & National Medical Research Council
  • 2021-present Scientific Expert, Global Data Collaborative for Cardiovascular Population Health, Microsoft and Novartis Foundation
  • 2021 European Society of Cardiology Heart Failure Guidelines Task Force
  • 2021 Co-Chair, Roadmap for Digital Health in Cardiology, World Heart Federation (WHF)
  • 2020-present  Member, ESC Global Affairs Committee
  • 2018, 2020-2023  Full Member, Committee of the Education & Management Division on Clinical Applications of Cardiac Bio-Markers (C-CB) for International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
  • 2019  Member, Global Health Programme Committee Group, European Society of Cardiology
  • 2019  Asia Pacific Representative, World Heart Federation Science Committee

 

Awards

  • 2022 Experscape Expert in Obesity
  • 2021 Clarivate’s Highly Cited Researcher 2021 in the category of Clinical Medicine -    https://recognition.webofscience.com/awards/highly-cited/2021/
  • 2021 Recognized as a World Expert by Expertscape’s PubMed-based algorithms
    • Top 0.1% of scholars writing about Heart Failure over the past 10 years
    • Heart Failure: Worldwide - Expertscape.com
  • 2021 International Honorary Fellow of the Heart Failure Society of America 2021
  • 2020  Lee Foundation 2020 (ADOPT research) – Received S$2.28M - 'Arresting Heart Disease in Diabetics' under the Singhealth Duke NUS Cardiovascular Sciences Academic Clinical Programme
  • 2020  2nd prize for SingHealth Duke-NUS Research Team Award 2020 - "Asian neTwork for Translation Research and Cardiovascular Trials (ATTRaCT)"
  • 2019  Paul Dudley White International Scholar Award – To Recognize the Authors with the Highest Ranked Abstract from New Zealand at Scientific Sessions 2019   
  • 2019  National Medical Research Council Clinician Scientist Award (Senior Investigator Category)
  • 2019  A*STAR Awards 2019: Borderless Award (awarded to ATTRaCT program; PI/ program director: Carolyn Lam SP)

 

Research Interest

• Heart Failure
• Clinical Trials
• Echocardiography
• Hemodynamics
• Biomarkers
• Sex Differences
• Epidemiology

Selected Publications

1. Jasper Tromp, Wouter Ouwerkerk, Tiew-Hwa K. Teng, John G. F. Cleland, Sahiddah Bamadha,  Christiane E. Angermann, Ulf Dahlstrom, Wan Ting Tay, Kenneth Dickstein, Georg Ertl, Mahmoud Hassanein, Sergio V. Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Sean P Collins, Gerasimos Filippatos, Carolyn SP Lam. Global Disparities in Prescription of Guideline-Recommended Drugs for Heart Failure with Reduced Ejection.  European Heart Journal.  Feb 2022.  JIF: 22.673

2. Carolyn SP Lam. How to incorporate sex and gender into the design of cardiovascular clinical trials. Circulation. 2022 Feb 15;145(7):499-501. doi: 10.1161/CIRCULATIONAHA.121.058771. JIF: 23.603

3. Subodh Verma, Nitish K Dhingra, Javed Butler, Stefan D Anker, Joao Pedro Ferreira, Gerasimos Filippatos, James L Januzzi, Carolyn SP Lam, Naveed Sattar, Barbara Peil, Matias Nordaby, Martina Brueckmann, Stuart JPocock, Faiez Zannad Milton Packer. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes & Endocrinology. 2021 Nov 30;S2213-8587(21)00292-8. doi: 10.1016/S2213-8587(21)00292-8. Online ahead of print. JIF: 25.340

4. Birgit Vogel, Monica Acevedo, Yolande Appelman, C Noel Bairey Merz, Alaide Chieffo, Gemma A Figtree, Mayra Guerrero, Vijay Kunadian, Carolyn SP Lam, Angela H E M Maas, Anastasia S Mihailidou, Agnieszka Olszanecka, Jeanne E Poole, Clara Saldarriaga, Jacqueline Saw, Liesl Zühlke, Roxana Mehran. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. The Lancet. 2021 Jun 19;397(10292):2385-2438. doi: 10.1016/S0140-6736(21)00684-X. Epub 2021 May 16. JIF: 60.392

5. Carolyn SP Lam, Chinthanie Ramasundarahettige, Kelley R.H. Bran ch,Naveed Sattar, Julio Rosenstock, Richard Pratley, Stefano Del Prato, Renato D. Lopes, Elisabeth Niemoeller, Nardev S. Khurmi, Seungjae Baek, Hertzel C. Gerstein. Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. November 2021. JIF: 23.603

6. Carolyn SP Lam, João Pedro Ferreira, Egon Pfarr4, David Sim, Hiroyuki Tsutsui, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Stuart J. Pocock, Naveed Sattar, Subodh Verma, Martina Brueckmann, Janet Schnee, Daniel Cotton, Faiez Zannad, Milton Packer. Regional and Ethnic Influences on the Response to Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction: the EMPEROR-Reduced trial. European Heart Journal. May 2021. JIF: 22.673

7. Carolyn SP Lam, Greg D Gamble, Lieng H Ling, David Sim, Kui Toh Gerard Leong, Poh Shuan Daniel Yeo, Hean Yee Ong, Fazlur Jaufeerally, Tze P Ng, Vicky A Cameron, Katrina Poppe, Mayanna Lund, Gerry Devlin, Richard Troughton, A. Mark Richards*, Robert N Doughty *(*Co-senior authors); Mortality Associated With Heart Failure With Preserved Versus Reduced Ejection Fracton In A Prospective International Multi-Ethnic Cohort Study. European Heart Journal. 2018 May 21;39(20):1770-1780. doi: 10.1093/eurheartj/ehy005. JIF: 22.673

8. Subodh Verma, Nitish K. Dhingra, Javed Butler, Stefan D. Anker, Joao Pedro Ferreira, Gerasimos Filippatos, James L. Januzzi, Carolyn SP Lam, Naveed Sattar, Barbara Peil, Matias Nordaby, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, and Milton Packer for the EMPEROR-Reduced Trial Committees and Investigators. Efficacy and Safety of Empagliflozin According to Doses and Combinations of Other Treatments for Heart Failure: A Post Hoc Analysis of the EMPEROR-Reduced Randomized Trial. The Lancet Diabetes & Endocrinology. November 2021. JIF: 25.340

9. Jasper Tromp, Milton Packer, Carolyn SP Lam. The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. European Journal of Heart Failure. 2021 Oct 16. doi: 10.1002/ejhf.2363. JIF: 11.627

10. Carolyn SP Lam, Hillary Mulder, Yuri Lopatin, Jose B Vazquez-Tanus, David Siu, Justin Ezekowitz, Burkert Pieske, Christopher M O'Connor, Lothar Roessig, Mahesh J Patel, Kevin J Anstrom, Adrian F Hernandez, Paul W Armstrong, VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. Journal of the American Heart Association. 2021 Nov 6;e021094. doi: 10.1161/JAHA.121.021094. Epub 2021 Nov 6. JIF: 4.605

11. Jasper Tromp, Wouter Ouwerkerk, Dirk J. van Veldhuisen, Hans L. Hillege, A. Mark Richards, Peter van der Meer, Inder S. Anand, Carolyn SP Lam (co-corresponding author), Adriaan A. Voors. A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction. JACC Heart Failure September 2021. JIF: 8.750

12. S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. Böhm, H.-P. Brunner–La Rocca, D.-J. Choi, V. Chopra, E. Chuquiure-Valenzuela, N. Giannetti, J.E. Gomez-Mesa, S. Janssens, J.L. Januzzi, J.R. Gonzalez-Juanatey, B. Merkely, S.J. Nicholls, S.V. Perrone, I.L. Piña, P. Ponikowski, M. Senni, D. Sim, J. Spinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, J. Zhang, P. Carson, Carolyn SP Lam, N. Marx, C. Zeller, N. Sattar, W. Jamal, S. Schnaidt, J.M. Schnee, M. Brueckmann, S.J. Pocock, F. Zannad, and M. Packer, for the EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine. August 2021. JIF: 74.699

13. Wan Ting Tay, Tiew-Hwa Katherine Teng, Oliver Simon, Wouter Ouwerkerk, Jasper Tromp, Robert N Doughty, Mark Richards, Chung-Lieh Hung, Yan Qin, Than Aung, Inder Anand, Carolyn SP Lam. Readmissions, death and its associated predictors in heart failure with preserved versus reduced ejection fraction. Journal of the American Heart Association. 2021 Nov 16;10(22):e021414. doi: 10.1161/JAHA.121.021414. Epub 2021 Oct 20. JIF: 4.605 

14. Hertzel C. Gerstein, Naveed Sattar, Julio Rosenstock, Chinthanie Ramasundarahettige, Richard Pratley, Renato D. Lopes, Carolyn SP Lam, Nardev S. Khurmi, Laura Heenan, Stefano Del Prato, Leanne Dyal, Kelley Branch.  Efpeglenatide, Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. June 2021.  New England Journal of Medicine. doi:10.1056/NEJMoa2108269 JIF: 74.699

15. Shih-Chieh Chien, Chanchal Chandramouli, Chi-In Lo, Chao-Feng Lin, Kuo-Tzu Sung, Wen-Hung Huang, Yau-Huei Lai, Chun-Ho Yun, Cheng-Huang Su, Hung-I Yeh, Ta-Chuan Hung, Chung-Lieh Hung, Carolyn SP Lam. Associations of obesity and malnutrition with cardiac remodelling and cardiovascular outcomes in Asian adults: A cohort study (Short title: Double burden of obesity and malnutrition on cardiac outcomes in Asians). PLOS Medicine. May 2021. JIF: 10.500

16. Carolyn SP Lam, Scott D. Solomon. Nomenclature in Heart Failure: Heart Failure with Reduced, Mildly Reduced and Normal Ejection Fraction. Journal of the American College of Cardiology. April 2021. JIF: 18.639 

17. Martin Cowie and Carolyn SP Lam.  Remote monitoring and digital health tools in cardiovascular disease management.  Nature Reviews Cardiology. 6 April 2021. https://doi.org/10.1038/s41569-021-00548-x. JIF: 20.260

18. Jasper Tromp, Jennifer A. Bryant, Xuanyi Jin, Gijs van Woerden, Salma Asali, Han Yiying, Oi Wah Liew, Jenny Chong Pek Ching, Fazlur Jaufeerally, Seet Yoong Loh, David Sim, Sheldon Lee, Dinna Soon, Wan Ting Tay, Milton Packer, Dirk J. van Veldhuisen, Calvin Chin, A Mark Richards, Carolyn SP Lam. Epicardial fat in heart failure with reduced versus preserved ejection fraction.  European Journal of Heart Failure. 16 March 2021. doi:10.1002/ejhf.2156. JIF: 11.627

19. Carolyn SP Lam, Robert Wood, Muthiah Vaduganathan, Hector Bueno, Alex Chin, Gabriela Luporini Saraiva, Elisabeth Sörstadius, Theo Tritton, Joseph Thomas, Lei Qin. Contemporary economic burden in a real-world heart failure population with Commercial and Medicare Supplemental Plans. Clinical Cardiology. 11 March 2021. https://doi.org/10.1002/clc.23585 JIF: 2.248 

20. Carolyn SP Lam, Avraham Karasik, Cheli Melzer-Cohen,,Matthew A. Cavender, Shun Kohsaka, Anna Norhammar, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod on behalf of the CVD-REAL Investigators and Study Group. Association of SGLT2 inhibitors with outcomes in Type 2 diabetes with reduced and preserved left ventricular ejection fraction — Analysis from the CVD-REAL 2 Study. Diabetes, Obesity and Metabolism. February 2021. https://doi.org/10.1111/dom.14356 JIF: 5.9

21. Jasper Tromp, Brian L. Claggett, Jiankang Liu, Alice M. Jackson, Pardeep S. Jhund, Lars Kober, Jiri Widimsky, Sergey Boytsov, Vijay Chopra, Inder S. Anand, Junbo Ge, Chen-Huan Chen, Aldo P. Maggioni, Felipe Martinez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Margaret M. Redfield, Jean L. Rouleau, Dirk J. Van Veldhuisen, Faiez Zannad, Michael R. Zile, Adel R. Rizkala, Akiko Inubushi-Molessa, Martin P. Lefkowitz, Victor C. Shi, John J.V. McMurray, Scott D. Solomon, Carolyn SP Lam on behalf of the PARAGON-HF Investigator.  Global Differences in Heart Failure in Preserved Ejection Fraction: the PARAGON-HF trial.  Circulation: Heart Failure. February 2021. JIF: 5.420

22. Jasper Tromp*, Samantha M.A. Paniagua*, Emily S. Lau, Norrina B. Allen, Michael J. Blaha, Ron Gansevoort, Hans Hillege, Douglas E. Lee, Daniel Levy, Vasan S. Ramachandran, Pim van der Harst, Wiek van Gilst, Martin G. Larson, Sanjiv J. Shah*, Rudolf A. de Boer*, Carolyn SP Lam*#, Jennifer E. Ho*#.  Age-dependent Associations of Risk Factors with Heart Failure.  British Medical Journal February 2021. JIF: 30.223 *these authors contributed equally #co-last author

23. THK Teng, WT Tay, AM Richards, TSM Chew, I Anand, W Ouwerkerk, C Chandramouli, W Huang, C Lawson, UT Kadam, J Yap, SL Lim, C-L Hung, MR MacDonald, SY Loh, W Shimizu, J Tromp, Carolyn SP Lam. Socioeconomic status and outcomes in heart failure with reduced ejection fraction from Asia. Circulation: Cardiovascular Quality and Outcomes. 24 March 2021. doi: 10.1161/CIRCOUTCOMES.120.006962. JIF: 5.07

24. Chorh Chuan Tan, Carolyn SP Lam, David B. Matchar, Yoong Kang Zee, John E.L. Wong.  Singapore’s Healthcare System: Key features, Challenges and Shifts.  The Lancet. 2021 Sep 18;398(10305):1091-1104. doi: 10.1016/S0140-6736(21)00252-X. Epub 2021 Sep 2. JIF: 60.392

25. Kanako Teramoto, Jasper Tromp, Carolyn SP Lam.  Heart Failure or Heart Success? Cardiovascular Research Onlife. https://doi.org/10.1093/cvr/cvab022 13 February 2021.  JIF: 8.68

26. Janice Y Chyou, Wan Ting Tay, Inder S Anand, Tiew-Hwa Katherine Teng, Jonathan JL Yap, Michael R MacDonald, Vijay Chopra, Seet Yoong Loh, Wataru Shimizu, Imran Zainal Abidin, ASIAN-HF Investigators, A Mark Richards, Javed Butler, Carolyn SP Lam. Electroanatomic Ratios and Mortality in Patients with Heart Failure: Insights from the Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) Registry. J Am Heart Assoc January 2021 JIF: 4.66

27. Carolyn SP Lam, Adriaan A. Voors, Piotr Ponikowski, John J.V. McMurray, Scott D. Solomon. Time to rename the Middle Child of Heart Failure: Heart Failure with Mildly Reduced Ejection Fraction.  European Heart Journal 2020 Jul 1;41(25):2353-2355. doi: 10.1093/eurheartj/ehaa158. JIF: 22.637

28. Carolyn SP Lam, Anna Giczewska, Karen Sliwa, Frank Edelmann, Jens Refsgaard, Edimar Bocchi, Justin A. Ezekowitz, Adrian F. Hernandez, Christopher M. O’Connor, Lothar Roessig, Mahesh J. Patel, Burkert Pieske, Kevin J. Anstrom, Paul W. Armstrong, on behalf of the VICTORIA Study Group. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights from the VICTORIA Trial. JAMA Cardiol. 2021 Jun 1;6(6):706-712. doi: 10.1001/jamacardio.2020.6455. JIF: 12.794

29. Sanjiv Shah, Sandra Sanders-van Wijk, Jasper Tromp, Lauren Beussink-Nelson, Camilla Hage, Sara Svedlun, Antti Saraste, Stanley Swat, Cynthia Sanchez, Joyce Njoroge, Ru-San tan, Maria Fermer, L-Ming Gan, Lars Lund, Carolyn SP Lam. Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study. Circulation. October 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.045810 JIF: 23.603

30. Paul W Armstrong, Carolyn SP Lam, Kevin J Anstrom, Justin Ezekowitz, Adrian F Hernandez, Christopher M O’Connor, Burkert Pieske, Piotr Ponikowski, Sanjiv J Shah, Scott D Solomon, Adriaan A Voors, Lilin She, Vanja Vlajnic, Francine Carvalho, Luke Bamber, Robert O Blaustein, Lothar Roessig, Javed Butler on behalf of the VITALITY-HFpEF Study Group. Effect of Vericiguat versus Placebo on Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA 2020 Oct 20;324(15):1512-1521. doi: 10.1001/jama.2020.15922. JIF: 45.540 

 

Research Trials

  • 2022   Baseline and repeat NT-proBNP in patients with Heart Failure
  • 2021  Arresting Heart Disease in Diabetics, SingHealth Duke NUS Cardiovascular Sciences Academic Clinical Programme
  • 2020-2024  Asian Diabetes Outcomes Prevention Trial (ADOPT), NMRC CTG-ICT
  • 2019-2023  Cardiovascular Clinical Trials in Asia: Asian Diabetes Outcomes Prevention Trial (ADOPT), NMRC Clinician Scientist Award
  • 2019-2023  Cardiovascular Clinical Trials in Asia: Asian Diabetes Outcomes Prevention Trial (ADOPT), Roche Diagnostics
  • 2017-2018  eKo.ai, A*Star
  • 2017-2018  Asian Sudden Cardiac Death in Heart Failure 2 (ASIAN-HF2 study), Bayer
  • 2015-2018  Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF study), Bayer
  • 2015-2017  Asian Diabetes Outcomes Registry (ADORE)
  • 2015  Metabolomic Profiling In Heart Failure With Preserved Vs Reduced Ejection Fraction
  • 2015-2017  Coronary Flow Reserve in Heart Failure with Preserved Ejection Fraction (CFR-HFpEF)
  • 2015-2021  Programme Lead of the Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), A*Star BMRC
  • 2014-2019  NMRC Clinician Scientist Award: Clinical Trials in Heart Failure
  • 2014-2017  Toll-like receptor 2 as a therapeutic target in heart failure
  • 2014-2016  Randomised, controlled pilot study to assess the role of IV ferric carboxymaltose in Asian patients with HF
  • 2014-2019  REnal SymPathECTomy in Heart Failure (RESPECT-HF) Study
  • 2014  Electrocardiographic Parameters in Asian Versus Western Adults
  • 2013-2018  Theme 1 of National Medical Research Council Centre Grant
  • 2013  A randomized, double-blind, crossover study to assess the effects of LCZ696 and valsartan in Asian patients with salt-sensitive hypertension
  • 2011-2016  Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF study), Boston Scientific
  • 2010-2012  Outcome in Patients with Heart Failure with a Preserved Left Ventricular Ejection Fraction (the “PEOPLE” study)
  • 2010-2013  Prospective compArison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fraction “PARAMOUNT”, Novartis
  • 2009-2012  Biomarkers and Management of Cardiovascular Disease: Singapore, Heart Failure Outcomes and Phenotypes (the “SHOP” study)